Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 295-300

  Patil, S ^a   Figlin, R A ^b   Hutson, T E ^c   Michaelson, M D ^d   Negrier S ^e   Kim, S T ^f   Huang, X ^f   Motzer, R J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^e CENTRE LÉON BÉRARD   (France)

^f PFIZER INC   (United States)

Author keywords

Interferon ; Memorial Sloan Kettering Cancer Center risk groups; Prognostic factors; Renal cell carcinoma; Sunitinib

Indexed keywords

ALPHA INTERFERON; CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE; SUNITINIB;

ARTICLE; BONE METASTASIS; CALCIUM BLOOD LEVEL; CANCER LOCALIZATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; NEPHRECTOMY; OVERALL SURVIVAL; PERFORMANCE MEASUREMENT SYSTEM; PHASE 3 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

EID: 79251574372     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq342     Document Type: Article

References (13)

1. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
2. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
3. Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer 2008; 6: s7-s13.
4. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
5. Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
7. Chen CH, George SL. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med 1985; 4: 39-46.
8. Royston P, Reitz M, Atzpodien J. An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer 2006; 94: 1785-1788.
9. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988; 48: 7310-7313.
10. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 348-353.
11. Mani S, Todd MB, Katz K, Poo WJ. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154: 35-40.
12. Negrier S, Escudier B, Gomez F et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002; 13: 1460-1468.
13. Heng DY, Xie W, Regan MM et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted agents: results from a large multicenter study. J Clin Oncol 2009; 27: 5794-5799.